Felodipine‑associated gingival overgrowth in a type 2 diabetic patient: A case report and literature review

Sun,Lin; Wang,Chengxin; Xi,Shugang; Zhou,Tong; Wang,Guixia; Gang,Xiaokun

doi:10.3892/etm.2019.7376

Felodipine‑associated gingival overgrowth in a type 2 diabetic patient: A case report and literature review

Authors:
- Lin Sun
- Chengxin Wang
- Shugang Xi
- Tong Zhou
- Guixia Wang
- Xiaokun Gang
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Developmental and Behavior Pediatrics, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: March 13, 2019 https://doi.org/10.3892/etm.2019.7376
Pages: 3399-3402
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gingival overgrowth (GO) includes gingival enlargement and hyperplasia and may be induced by certain drugs, including calcium channel blockers (CCBs), particularly first‑generation CCBs. However, to date, only few cases of GO induced by second‑ or third‑generation CCBs have been reported. The present study reports on a case of a 48‑year‑old diabetic male who was admitted to the First Hospital of Jilin University (Changchun, China) due to poor blood glucose control. This patient was diagnosed with GO. Review of the patient's medical history revealed diagnoses of type 2 diabetes and hypertension, as well as the use of felodipine, a second‑generation CCB, to control hypertension. The hypertensive drugs were replaced and the new drugs helped the patient control his blood glucose levels. Additionally, the patient was instructed on methods he could use to improve his oral hygiene, including rinsing of the teeth following each meal and increasing the frequency of tooth brushing per day. After 3 months, the clinical symptoms of GO were relieved. The relevant literature was also reviewed to gain an improved understanding of the correlation between GO and CCBs, as well as diabetes and poor oral hygiene.

View Figures

View References

1	Nyska A, Shemesh M, Tal H and Dayan D: Gingival hyperplasia induced by calcium channel blockers: Mode of action. Med Hypotheses. 43:115–118. 1994. View Article : Google Scholar : PubMed/NCBI
2	Lafzi A, Farahani RM and Shoja MA: Amlodipine-induced gingival hyperplasia. Med Oral Patol Oral Cir Bucal. 11:E480–E482. 2006.PubMed/NCBI
3	Joshi S and Bansal S: A rare case report of amlodipine-induced gingival enlargement and review of its pathogenesis. Case Rep Dent. 2013:1382482013.PubMed/NCBI
4	Fay AA, Satheesh K and Gapski R: Felodipine-influenced gingival enlargement in an uncontrolled type 2 diabetic patient. J Periodontol. 76:12172005. View Article : Google Scholar : PubMed/NCBI
5	Sucu M, Yuce M and Davutoglu V: Amlodipine-induced massive gingival hypertrophy. Can Fam Physician. 57:436–437. 2011.PubMed/NCBI
6	Hallmon WW and Rossmann JA: The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontol 2000. 21:176–196. 1999. View Article : Google Scholar : PubMed/NCBI
7	Seymour RA, Thomason JM and Ellis JS: The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 23:165–175. 1996. View Article : Google Scholar : PubMed/NCBI
8	Ono M, Tanaka S, Takeuchi R, Matsumoto H, Okada H, Yamamoto H, Makiyama Y, Hirayama T, Sakamaki T, Fujii A and Akimoto Y: Prevalence of Amlodipine-induced Gingival Overgrowth. Int J Oral-Med Sci. 9:96–100. 2010. View Article : Google Scholar
9	Hassell TM and Gilbert GH: Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement. Am J Pathol. 112:218–223. 1983.PubMed/NCBI
10	Casetta I, Granieri E, Desiderá M, Monetti VC, Tola MR, Paolino E, Govoni V and Calura G: Phenytoin-induced gingival overgrowth: A community-based cross-sectional study in Ferrara, Italy. Neuroepidemiology. 16:296–303. 1997. View Article : Google Scholar : PubMed/NCBI
11	Brunsvold M, Tomasovic J and Ruemping D: The measured effect of phenytoin withdrawal on gingival hyperplasia in children. ASDC J Dent Child. 52:417–421. 1985.PubMed/NCBI
12	Rateitschak-Plüss EM, Hefti A, Lörtscher R and Thiel G: Initial observation that cyclosporin-A induces gingival enlargement in man. J Clin Periodontol. 10:237–246. 1983. View Article : Google Scholar : PubMed/NCBI
13	Pisanty S, Rahamim E, Ben-Ezra D and Shoshan S: Prolonged systemic administration of cyclosporin A affects gingival epithelium. J Periodontol. 61:138–141. 1990. View Article : Google Scholar : PubMed/NCBI
14	Daly CG: Resolution of cyclosporin A (CsA)-induced gingival enlargement following reduction in CsA dosage. J Clin Periodontol. 19:143–145. 1992. View Article : Google Scholar : PubMed/NCBI
15	Barak S, Engelberg IS and Hiss J: Gingival hyperplasia caused by nifedipine. Histopathologic findings. J Periodontol. 58:639–642. 1987. View Article : Google Scholar : PubMed/NCBI
16	Romanos GE, Schröter-Kermani C, Hinz N, Herrmann D, Strub JR and Bernimoulin JP: Extracellular matrix analysis of nifedipine-induced gingival overgrowth: Immunohistochemical distribution of different collagen types as well as the glycoprotein fibronectin. J Periodontal Res. 28:10–16. 1993. View Article : Google Scholar : PubMed/NCBI
17	Miranda J, Brunet L, Roset P, Berini L, Farré M and Mendieta C: Prevalence and risk of gingival enlargement in patients treated with nifedipine. J Periodontol. 72:605–611. 2001. View Article : Google Scholar : PubMed/NCBI
18	Pernu HE, Oikarinen K, Hietanen J and Knuuttila M: Verapamil-induced gingival overgrowth: A clinical, histologic, and biochemic approach. J Oral Pathol Med. 18:422–425. 1989. View Article : Google Scholar : PubMed/NCBI
19	Miller CS and Damm DD: Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol. 63:453–456. 1992. View Article : Google Scholar : PubMed/NCBI
20	Mehta AV, Chidambaram B and O'Riordan AC: Verapamil-induced gingival hyperplasia in children. Am Heart J. 124:535–536. 1992. View Article : Google Scholar : PubMed/NCBI
21	Giustiniani S, Robustelli della Cuna F and Marieni M: Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol. 15:247–249. 1987. View Article : Google Scholar : PubMed/NCBI
22	Fattore L, Stablein M, Bredfeldt G, Semla T, Moran M and Doherty-Greenberg JM: Gingival hyperplasia: A side effect of nifedipine and diltiazem. Spec Care Dentist. 11:107–109. 1991. View Article : Google Scholar : PubMed/NCBI
23	Godfraind T: Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther. 19:501–515. 2014. View Article : Google Scholar : PubMed/NCBI
24	Godfraind T: Mechanisms of action of calcium entry blockers. Fed Proc. 40:2866–2871. 1981.PubMed/NCBI
25	Soward AL, Vanhaleweyk GL and Serruys PW: The haemodynamic effects of nifedipine, verapamil and diltiazem in patients with coronary artery disease. A review. Drugs. 32:66–101. 1986. View Article : Google Scholar : PubMed/NCBI
26	Bose T, Cieślar-Pobuda A and Wiechec E: Role of ion channels in regulating Ca²⁺ homeostasis during the interplay between immune and cancer cells. Cell Death Dis. 6:e16482015. View Article : Google Scholar : PubMed/NCBI
27	Lombardi T, Fiore-Donno G, Belser U and Di Felice R: Felodipine-induced gingival hyperplasia: A clinical and histologic study. J Oral Pathol Med. 20:89–92. 1991. View Article : Google Scholar : PubMed/NCBI
28	Thomas P, Tolstoy R and Duraisingh L: Amlodipine induced gingival hyperplasia: A case report. Int J Basic Clin Pharmacol. 805–807. 2015.(In Chinese). View Article : Google Scholar
29	Gong Y, Lu J, Ding X and Yu Y: Effect of adjunctive roxithromycin therapy on interleukin-1β, transforming growth factor-β1 and vascular endothelial growth factor in gingival crevicular fluid of cyclosporine A-treated patients with gingival overgrowth. J Periodontal Res. 49:448–457. 2014. View Article : Google Scholar : PubMed/NCBI
30	Matsumoto H, Takeuchi R, Ono M, Akimoto Y, Kobayashi N and Fujii A: Drug-induced gingival overgrowth and its tentative pharmacotherapy. Jpn Dent Sci Rev. 46:11–16. 2010. View Article : Google Scholar
31	Van Dis ML, Allen CM and Neville BW: Erythematous gingival enlargement in diabetic patients: A report of four cases. J Oral Maxillofac Surg. 46:794–798. 1988. View Article : Google Scholar : PubMed/NCBI
32	Padmanabhan S and Dwarakanath CD: Severe gingival enlargement associated with aggressive periodontitis. J Indian Soc Periodontol. 17:115–119. 2013. View Article : Google Scholar : PubMed/NCBI
33	Agrawal AA: Gingival enlargements: Differential diagnosis and review of literature. World J Clin Cases. 3:779–788. 2015. View Article : Google Scholar : PubMed/NCBI
34	Reali L, Zuliani E, Gabutti L, Schönholzer C and Marone C: Poor oral hygiene enhances gingival overgrowth caused by calcineurin inhibitors. J Clin Pharm Ther. 34:255–260. 2009. View Article : Google Scholar : PubMed/NCBI
35	Khzam N, Bailey D, Yie HS and Bakr MM: Gingival enlargement induced by felodipine resolves with a conventional periodontal treatment and drug modification. Case Rep Dent. 2016:10959272016.PubMed/NCBI